Cerebrolysin : The Next Evolution of Medicine

Product Information

All customers represent and warrant that through their own review and study that they are fully aware and knowledgeable about the following: Alvarez et al (2008) Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate–severe traumatic brain injury https://www.ncbi.nlm.nih.gov/pubmed/18273537 We identified six randomised controlled trials with a total of 597 participants that were eligible for inclusion in the 2013 review. No new studies were eligible for inclusion in this update. Participants in the included studies, where dementia severity was reported, had mild to moderate severity of vascular dementia (four trials). The included studies tested varying doses and duration of Cerebrolysin treatment. Follow‐up ranged from 15 days to three years. Five of included studies were conducted in China (three studies), Russia (one study), and Romania (one study), while relevant information of other study was unclear. Where details of funding were available, all studies were supported by the pharmaceutical industry (three studies).

W.-D. Heiss, M. Brainin, N. M. Bornstein, J. Tuomilehto, Z. Hong, and Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators, “Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial,” Stroke, vol. 43, no. 3, pp. 630–636, Mar. 2012, doi: 10.1161/STROKEAHA.111.628537. Plosker GL, Gauthier S (2009) Cerebrolysin. Drugs Aging 26(11):893–915. https://doi.org/10.2165/11203320-000000000-00000 Heiss WD, Brainin M, Bornstein NM et al. (2012) Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke; a journal of cerebral circulation 43, 630-636. Amiri-Nikpour et al (2014) Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke https://www.ncbi.nlm.nih.gov/pubmed/25516711

Support

Chao Moses V, Rajagopal R, Lee Francis S (2006) Neurotrophin signalling in health and disease. Clin Sci 110(2):167–173. https://doi.org/10.1042/cs20050163 A few instances are that I do not need to "plan" as much when I am writing something out; before I would need to think of the sentence, its structure and flow before writing it out.

Ruether E, Husmann R, Kinzler E, Diabl E, Klingler D, Spatt J, Ritter R, Schmidt R, Taneri Z, Winterer W, Koper D, Kasper S, Rainer M, Moessler H (2001) A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer’s disease. Int Clin Psychopharmacol 16(5):253–263. https://doi.org/10.1097/00004850-200109000-00002 Ziganshina LE, Abakumova T, Vernay L (2017) Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev 4(4):CD007026–CD007026. https://doi.org/10.1002/14651858.CD007026.pub5

Safety

Alvarez XA, Alvarez I, Iglesias O et al. (2016) Synergistic Increase of Serum BDNF in Alzheimer Patients Treated with Cerebrolysin and Donepezil: Association with Cognitive Improvement in ApoE4 Cases. Int J Neuropsychopharmacol. Alvarez XA, Lombardi VR, Fernandez-Novoa L et al. (2000) Cerebrolysin reduces microglial activation in vivo and in vitro: a potential mechanism of neuroprotection. Journal of neural transmission Supplementum 59, 281-292. A clinical trial performed on more than 200 patients regarding the efficacy of Cerebrolysin in patients with stroke showed that it can improve cognition and motor function in post-stroke patients, which can be determined by several lab tests. In this clinical trial, patients were administered with Cerebrolysin, 72 hours after stroke and continued for 21 days. [iii] Side Effects of Cerebrolysin: Use only sterile, single use syringes (or single use one-way infusion kits). Recommended to use sterile plastic gloves.

C.-C. Chen, S.-T. Wei, S.-C. Tsaia, X.-X. Chen, and D.-Y. Cho, “Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients: double-blind, placebo-controlled, randomized study,” Br. J. Neurosurg., vol. 27, no. 6, pp. 803–807, Dec. 2013, doi: 10.3109/02688697.2013.793287.Nerve Growth Factor: NGF is a neuropeptide that regulates growth, survival, and proliferation of sensory neurons and sympathetic neurons. Research indicates that it is important in preventing programmed cell death in these populations of neurons. It is also important in the regulation of the immune system and is thought to protect pancreatic beta cells from apoptosis.

Muresanu DF, Ciurea AV, Gorgan RM, Gheorghita E, Florian SI, Stan H, Blaga A, Ianovici N, Iencean SM, Turliuc D, Davidescu HB, Mihalache C, Brehar FM, Mihaescu AS, Mardare DC, Anghelescu A, Chiparus C, Lapadat M, Pruna V, Mohan D, Costea C, Costea D, Palade C, Bucur N, Figueroa J, Alvarez A (2015) A retrospective, multi-center cohort study evaluating the severity- related effects of cerebrolysin treatment on clinical outcomes in traumatic brain injury. CNS Neurol Disord Drug Targets 14(5):587–599. https://doi.org/10.2174/1871527314666150430162531 Cerebrolysin has indication-specific dosing. The most common regime for improving brain function is IM injections of 5 ml daily. The course of treatment is 4 weeks unless otherwise prescribed by your attending physician.

Learn More

Ren et al (2007) Cerebrolysin enhances functional recovery following focal cerebral infarction in rats https://www.ncbi.nlm.nih.gov/pubmed/17473393 No clinical studies have tested whether cerebrolysin can prevent dementia, but some preclinical research supports the idea. In preclinical studies, cerebrolysin protected neurons and brain slices from damage [2] [3] [4], reduced inflammation [5], promoted the formation of new neural connections (synapses) [6], lessened cognitive impairment [7], and reduced the plaques and tangles common in Alzheimer’s patients [8] [9]. Whether these effects will occur in humans is unknown. APOE4 Carriers: Yanlu Z, Michael C, Zheng Gang Z, Yi Z, Li Z, Mei L, Talan Z, Stefan W, Hemma B, Asim M, Ye X (2018) Prospective, randomized, blinded, and placebo-controlled study of Cerebrolysin dose-response effects on long-term functional outcomes in a rat model of mild traumatic brain injury. J Neurosurg 129(5):1295–1304. https://doi.org/10.3171/2017.6.JNS171007 Sharma HS, Zimmermann-Meinzingen S, Johanson CE (2010) Cerebrolysin reduces blood-cerebrospinal fluid barrier permeability change, brain pathology, and functional deficits following traumatic brain injury in the rat. Ann N Y Acad Sci 1199:125–137. https://doi.org/10.1111/j.1749-6632.2009.05329.x Muresanu DF, Alvarez XA, Moessler H, Buia M, Stan A, Pintea D, Moldovan F, Popescu BO (2008) A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. J Neurol Sci 267(1-2):112–119. https://doi.org/10.1016/j.jns.2007.10.016